Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13,948 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Liposomal mitoxantrone monotherapy in patients with relapsed or refractory mature T-cell and natural killer-cell neoplasms: A phase 2, multicenter, open-label, single-arm trial.
Gao Y, Huang Y, Zhang Q, Yang H, Li Y, Li Y, Zhou M, Yang R, Xu B, Liu L, Yang Y, Peng Z, Yu D, Zhou H, Zhang R, Zhang H, Qi J, Xi Y, Xing X, Wang Z, Jing H, Shuang Y, Zhang X, Ma L, Jin H, Lin L, Li C, Xue J, Liu Y, Yuan J, Huang H. Gao Y, et al. Among authors: yu d. Cancer. 2025 Jan 1;131(1):e35672. doi: 10.1002/cncr.35672. Cancer. 2025. PMID: 39748491 Free PMC article. Clinical Trial.
Comparison of zuberitamab plus CHOP versus rituximab plus CHOP for the treatment of drug-naïve patients diagnosed with CD20-positive diffuse large B-cell lymphoma: a phase 3 trial.
Li Z, Jiang W, Zhou H, Cen H, Zhang M, Lv F, Zhang Q, Sun X, Liu L, Huang Y, Yang H, Gao S, He C, Yang W, Li W, Yu D, Yang Y, Cheng Y, Qian Z, Xiang Y, Guo Q, Xu B, Song Y, Zhang L, Lin L, Shen J, Yan F, Liu H, Zhang D, Wang J, Zhou M, Zhu X, Zhang W, Zhao W, Feng R, Zhang X, Jin J, Zhong M, Zhang M, Wang J, Jing H, Wang Z, Zhao H, Zhu J. Li Z, et al. Among authors: yu d. J Immunother Cancer. 2024 Oct 24;12(10):e008895. doi: 10.1136/jitc-2024-008895. J Immunother Cancer. 2024. PMID: 39455094 Free PMC article. Clinical Trial.
A phase 3 study of rituximab biosimilar HLX01 in patients with diffuse large B-cell lymphoma.
Shi Y, Song Y, Qin Y, Zhang Q, Han X, Hong X, Wang D, Li W, Zhang Y, Feng J, Yang J, Zhang H, Jin C, Yang Y, Hu J, Wang Z, Jin Z, Su H, Wang H, Yang H, Fu W, Zhang M, Zhang X, Chen Y, Ke X, Liu L, Yu D, Chen G, Wang X, Jin J, Sun T, Du X, Cheng Y, Yi P, Zhao X, Ma C, Cheng J, Chai K, Luk A, Liu E, Zhang X. Shi Y, et al. Among authors: yu d. J Hematol Oncol. 2020 Apr 16;13(1):38. doi: 10.1186/s13045-020-00871-9. J Hematol Oncol. 2020. PMID: 32299513 Free PMC article. Clinical Trial.
Long-term outcomes with HLX01 (HanliKang®), a rituximab biosimilar, in previously untreated patients with diffuse large B-cell lymphoma: 5-year follow-up results of the phase 3 HLX01-NHL03 study.
Qin Y, Song Y, Wang D, Bai O, Feng J, Sun X, Qiu L, Yang J, Yang Y, Wang Z, Hu J, Wang H, Su H, Jin Z, Qian W, Jin C, Zhang M, Yu D, Liu L, Chen G, Li Y, Sun T, Jin J, Bao H, Du X, Zhou H, Fu G, Shi Y. Qin Y, et al. Among authors: yu d. BMC Cancer. 2024 Jan 24;24(1):124. doi: 10.1186/s12885-024-11876-9. BMC Cancer. 2024. PMID: 38267866 Free PMC article. Clinical Trial.
Efficacy, Safety, and Population Pharmacokinetics of MW032 Compared With Denosumab for Solid Tumor-Related Bone Metastases: A Randomized, Double-Blind, Phase 3 Equivalence Trial.
Zhang S, Yin Y, Xiong H, Wang J, Liu H, Lu J, Zhang Q, Zhang L, Zhong J, Nie J, Lei K, Wang H, Yang S, Yao H, Wu H, Yu D, Ji X, Zhang H, Wu F, Xie W, Li W, Yao W, Zhong D, Sun H, Sun T, Guo Z, Wang R, Guo Y, Yu Z, Li D, Jin H, Song H, Chen X, Ma W, Hu Z, Liu D, Guo Y, Tang J, Jiang Z. Zhang S, et al. Among authors: yu d, yu z. JAMA Oncol. 2024 Apr 1;10(4):448-455. doi: 10.1001/jamaoncol.2023.6520. JAMA Oncol. 2024. PMID: 38329745 Free PMC article. Clinical Trial.
13,948 results
You have reached the last available page of results. Please see the User Guide for more information.